These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 23393603)
1. A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration. Ciaccioli G; Martins A; Rodrigues C; Vieira H; Calado P PLoS One; 2013; 8(2):e55848. PubMed ID: 23393603 [TBL] [Abstract][Full Text] [Related]
2. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration? Yan X; Uronen RL; Huttunen HJ Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880 [TBL] [Abstract][Full Text] [Related]
3. LRRK2, alpha-synuclein, and tau: partners in crime or unfortunate bystanders? Outeiro TF; Harvey K; Dominguez-Meijide A; Gerhardt E Biochem Soc Trans; 2019 Jun; 47(3):827-838. PubMed ID: 31085616 [TBL] [Abstract][Full Text] [Related]
4. Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization. Dominguez-Meijide A; Vasili E; König A; Cima-Omori MS; Ibáñez de Opakua A; Leonov A; Ryazanov S; Zweckstetter M; Griesinger C; Outeiro TF Sci Rep; 2020 Jul; 10(1):12827. PubMed ID: 32732936 [TBL] [Abstract][Full Text] [Related]
5. Phosphorylation modulates clearance of alpha-synuclein inclusions in a yeast model of Parkinson's disease. Tenreiro S; Reimão-Pinto MM; Antas P; Rino J; Wawrzycka D; Macedo D; Rosado-Ramos R; Amen T; Waiss M; Magalhães F; Gomes A; Santos CN; Kaganovich D; Outeiro TF PLoS Genet; 2014 May; 10(5):e1004302. PubMed ID: 24810576 [TBL] [Abstract][Full Text] [Related]
6. Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology. Esteves AR; Palma AM; Gomes R; Santos D; Silva DF; Cardoso SM Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2008-2023. PubMed ID: 30572013 [TBL] [Abstract][Full Text] [Related]
7. E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation. Íñigo-Marco I; Valencia M; Larrea L; Bugallo R; Martínez-Goikoetxea M; Zuriguel I; Arrasate M Proc Natl Acad Sci U S A; 2017 Sep; 114(39):E8274-E8283. PubMed ID: 28900007 [TBL] [Abstract][Full Text] [Related]
8. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases. Lee VM; Giasson BI; Trojanowski JQ Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877 [TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein and tau: teammates in neurodegeneration? Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339 [TBL] [Abstract][Full Text] [Related]
10. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. Permanne B; Sand A; Ousson S; Nény M; Hantson J; Schubert R; Wiessner C; Quattropani A; Beher D ACS Chem Neurosci; 2022 Apr; 13(8):1296-1314. PubMed ID: 35357812 [TBL] [Abstract][Full Text] [Related]
11. Interaction between α-synuclein and other proteins in neurodegenerative disorders. Jellinger KA ScientificWorldJournal; 2011; 11():1893-907. PubMed ID: 22125446 [TBL] [Abstract][Full Text] [Related]
12. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Muntané G; Dalfó E; Martinez A; Ferrer I Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584 [TBL] [Abstract][Full Text] [Related]
14. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Goedert M; Masuda-Suzukake M; Falcon B Brain; 2017 Feb; 140(2):266-278. PubMed ID: 27658420 [TBL] [Abstract][Full Text] [Related]
15. Abberant alpha-synuclein confers toxicity to neurons in part through inhibition of chaperone-mediated autophagy. Xilouri M; Vogiatzi T; Vekrellis K; Park D; Stefanis L PLoS One; 2009; 4(5):e5515. PubMed ID: 19436756 [TBL] [Abstract][Full Text] [Related]
16. The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. Lázaro DF; Dias MC; Carija A; Navarro S; Madaleno CS; Tenreiro S; Ventura S; Outeiro TF Acta Neuropathol Commun; 2016 Dec; 4(1):128. PubMed ID: 27938414 [TBL] [Abstract][Full Text] [Related]
17. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. Visanji NP; Lang AE; Kovacs GG Transl Neurodegener; 2019; 8():28. PubMed ID: 31508228 [TBL] [Abstract][Full Text] [Related]
18. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Lashuel HA Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655 [TBL] [Abstract][Full Text] [Related]
19. Monitoring the interactions between alpha-synuclein and Tau in vitro and in vivo using bimolecular fluorescence complementation. Torres-Garcia L; P Domingues JM; Brandi E; Haikal C; Mudannayake JM; Brás IC; Gerhardt E; Li W; Svanbergsson A; Outeiro TF; Gouras GK; Li JY Sci Rep; 2022 Feb; 12(1):2987. PubMed ID: 35194057 [TBL] [Abstract][Full Text] [Related]
20. Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein. Quint WH; Matečko-Burmann I; Schilcher I; Löffler T; Schöll M; Burmann BM; Vogels T J Alzheimers Dis; 2021; 80(2):813-829. PubMed ID: 33579845 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]